Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Pancreatic Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
Study leads
Anup Kasi, MD, MPH
Principal Investigator
The University of Kansas Cancer Center